Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-CWS versus BCG after TURBT in intermediate- and high-risk non-muscle-invasive bladder cancer
ChiCTR2100042774Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of nocardia rubra cell wall skeleton and bcg vaccine in bladder cancer and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Recurrence-free survival. Started Feb 2021; status: recruiting.
02
Drugs
nocardia rubra cell wall skeletonbcg vaccine
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2100042774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042774.